Skip to main content
. 2020 Jun 5;11:2835. doi: 10.1038/s41467-020-16696-6

Fig. 8. Repression of mTORC1 hyperactivity ameliorates focal hypermyelination in vivo.

Fig. 8

a Rapamycin represses mTORC1 signaling in sciatic nerves in vivo. Immunoblot for p-S6 in sciatic nerve lysates from Rab35 control and Rab35 cKOSC mice treated (from P12 until P70) with vehicle or Rapamycin. b–d Semithin section analysis of sciatic nerves from Rab35 cKOSC mice (P70) following vehicle or Rapamycin treatment and quantification of the percentage of fibers carrying myelin degeneration. Data represent mean ± SEM. b: 5.39% ± 0.47 vehicle-treated, 4.31% ± 0.33 Rapamycin-treated, one-tailed non-parametric Mann–Whitney t-test, *p = 0.048; myelin outfoldings c: 9.33% ± 1.00 vehicle-treated, 8.78% ± 0.70 Rapamycin-treated, one-tailed non-parametric Mann–Whitney t-test, p = 0.45; and tomacula d: vehicle-treated, 6.92% ± 0.39 and Rapamycin-treated, 5.18% ± 0.39, two-tailed nonparametric Mann–Whitney, **p = 0.0041. e Quantification of the number of myelinated fibers carrying aberrant myelin in Rab35 cKOSC vehicle and Rapamycin-treated sciatic nerves. Altered fibers are expressed as a percentage of the total number of fibers. Data are from n = 7 mice from each genotype. Data represent mean ± SEM. Source Data file for numerical source data and unprocessed blots.